Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run?

Collegium Pharmaceutical (COLL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Dec 4, 2025

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Dec 4, 2025

Why 2025 is a Dynamic and Transformative Year for Collegium

COLL's bold buybacks, board refresh and expanding ADHD push highlight a year of strategic moves and rising momentum.

Zacks Investment Research • Nov 21, 2025

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Nov 18, 2025

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies London Healthcare Conference Presentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m.

GlobeNewsWire • Nov 12, 2025

Collegium Pharmaceutical: Another Solid Quarter

Collegium Pharmaceutical, Inc. just delivered standout Q3 results, with EPS and revenue significantly surpassing expectations, driving a 15% stock surge. COLL focuses on pain management treatments and expanded into ADHD with the recent Jornay PM acquisition, strengthening its product portfolio. Despite insider selling and a notable short interest, COLL maintains a strong cash position and manageable long-term debt.

Seeking Alpha • Nov 10, 2025

Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript

Collegium Pharmaceutical, Inc. ( COLL ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Ian Karp Vikram Karnani - CEO, President, Executive VP & Director Scott Dreyer - Executive VP & Chief Commercial Officer Colleen Tupper - Executive VP & CFO Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Jeevan Larson - Truist Securities, Inc., Research Division John Gionco - Needham & Company, LLC, Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Presentation Operator Greetings, and welcome to the Collegium Pharmaceuticals Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Nov 7, 2025

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3'25 with Cash, Cash Equivalents and Marketable Securities of $285.9 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.

GlobeNewsWire • Nov 6, 2025

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Nov 6, 2025

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.88 per share. This compares to earnings of $1.61 per share a year ago.

Zacks Investment Research • Nov 6, 2025